192 related articles for article (PubMed ID: 38360038)
21. Treatment of hereditary autoinflammatory diseases.
Ter Haar NM; Frenkel J
Curr Opin Rheumatol; 2014 May; 26(3):252-8. PubMed ID: 24667287
[TBL] [Abstract][Full Text] [Related]
22. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.
Romano M; Arici ZS; Piskin D; Alehashemi S; Aletaha D; Barron KS; Benseler S; Berard R; Broderick L; Dedeoglu F; Diebold M; Durrant KL; Ferguson P; Foell D; Hausmann J; Jones OY; Kastner DL; Lachmann HJ; Laxer RM; Rivera D; Ruperto N; Simon A; Twilt M; Frenkel J; Hoffman H; de Jesus AA; Kuemmerle-Deschner JB; Ozen S; Gattorno M; Goldbach-Mansky R; Demirkaya E
Ann Rheum Dis; 2022 Jul; 81(7):907-921. PubMed ID: 35623638
[TBL] [Abstract][Full Text] [Related]
23. Clinical presentation and genetic variants in patients with autoinflammatory diseases: results from the German GARROD registry.
Blank N; Kötter I; Schmalzing M; Rech J; Krause K; Köhler B; Kaudewitz D; Nitschke M; Haas CS; Lorenz HM; Krusche M
Rheumatol Int; 2024 Feb; 44(2):263-271. PubMed ID: 37747561
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience.
Russo RA; Melo-Gomes S; Lachmann HJ; Wynne K; Rajput K; Eleftheriou D; Edelsten C; Hawkins PN; Brogan PA
Rheumatology (Oxford); 2014 Apr; 53(4):665-70. PubMed ID: 24352339
[TBL] [Abstract][Full Text] [Related]
25. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review.
Ter Haar N; Lachmann H; Özen S; Woo P; Uziel Y; Modesto C; Koné-Paut I; Cantarini L; Insalaco A; Neven B; Hofer M; Rigante D; Al-Mayouf S; Touitou I; Gallizzi R; Papadopoulou-Alataki E; Martino S; Kuemmerle-Deschner J; Obici L; Iagaru N; Simon A; Nielsen S; Martini A; Ruperto N; Gattorno M; Frenkel J;
Ann Rheum Dis; 2013 May; 72(5):678-85. PubMed ID: 22753383
[TBL] [Abstract][Full Text] [Related]
26. Use of the Auto-inflammatory Disease Activity Index to monitor disease activity in patients with colchicine-resistant Familial Mediterranean Fever, Mevalonate Kinase Deficiency, and TRAPS treated with canakinumab.
Koné-Paut I; Piram M; Benseler S; Kuemmerle-Deschner JB; Jansson A; Rosner I; Tommasini A; Murias S; Karadag O; Levy J; McCreddin S; Migliaccio M; De Benedetti F
Joint Bone Spine; 2022 Nov; 89(6):105448. PubMed ID: 35944600
[TBL] [Abstract][Full Text] [Related]
27. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.
Romano M; Arici ZS; Piskin D; Alehashemi S; Aletaha D; Barron K; Benseler S; Berard RA; Broderick L; Dedeoglu F; Diebold M; Durrant K; Ferguson P; Foell D; Hausmann JS; Jones OY; Kastner D; Lachmann HJ; Laxer RM; Rivera D; Ruperto N; Simon A; Twilt M; Frenkel J; Hoffman HM; de Jesus AA; Kuemmerle-Deschner JB; Ozen S; Gattorno M; Goldbach-Mansky R; Demirkaya E
Arthritis Rheumatol; 2022 Jul; 74(7):1102-1121. PubMed ID: 35621220
[TBL] [Abstract][Full Text] [Related]
28. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS).
Kuemmerle-Deschner JB; Ramos E; Blank N; Roesler J; Felix SD; Jung T; Stricker K; Chakraborty A; Tannenbaum S; Wright AM; Rordorf C
Arthritis Res Ther; 2011 Feb; 13(1):R34. PubMed ID: 21356079
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the clinical diagnostic criteria and the results of the next-generation sequence gene panel in patients with monogenic systemic autoinflammatory diseases.
Sözeri B; Demir F; Sönmez HE; Karadağ ŞG; Demirkol YK; Doğan ÖA; Doğanay HL; Ayaz NA
Clin Rheumatol; 2021 Jun; 40(6):2327-2337. PubMed ID: 33165748
[TBL] [Abstract][Full Text] [Related]
30. Pattern and diagnostic evaluation of systemic autoinflammatory diseases other than familial Mediterranean fever among Arab children: a multicenter study from the Pediatric Rheumatology Arab Group (PRAG).
Al-Mayouf SM; Almutairi A; Albrawi S; Fathalla BM; Alzyoud R; AlEnazi A; Abu-Shukair M; Alwahadneh A; Alsonbul A; Zlenti M; Khawaja E; Abushhaiwia A; Khawaja K; AlMosawi Z; Madan W; Almuatiri M; Almuatiri N;
Rheumatol Int; 2020 Jan; 40(1):49-56. PubMed ID: 31741047
[TBL] [Abstract][Full Text] [Related]
31. Growth Parameters of Turkish Children With an Autoinflammatory Disease Before and After Canakinumab Treatment.
Balci S; Ekinci RMK; Dogruel D; Altintas DU; Yilmaz M
Indian Pediatr; 2020 Jul; 57(7):637-640. PubMed ID: 32727940
[TBL] [Abstract][Full Text] [Related]
32. Real-world safety and effectiveness of canakinumab in patients with cryopyrin-associated periodic fever syndrome: a long-term observational study in Japan.
Hosono K; Kato C; Sasajima T
Clin Exp Rheumatol; 2022 Sep; 40(8):1543-1553. PubMed ID: 36106540
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy of canakinumab in hyperimmunoglobulin D syndrome.
Ozdemir Isik O; Karadag DT; Tekeoglu S; Yazici A; Cefle K; Cefle A
Int J Rheum Dis; 2024 Jan; 27(1):e14857. PubMed ID: 37578023
[TBL] [Abstract][Full Text] [Related]
34. Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.
Kuemmerle-Deschner JB; Hofer F; Endres T; Kortus-Goetze B; Blank N; Weißbarth-Riedel E; Schuetz C; Kallinich T; Krause K; Rietschel C; Horneff G; Benseler SM
Rheumatology (Oxford); 2016 Apr; 55(4):689-96. PubMed ID: 26667214
[TBL] [Abstract][Full Text] [Related]
35. The assessment of autoinflammatory disease classification criteria (Eurofever/PRINTO) in a real-life cohort.
Çağlayan Ş; Mardinoğlu G; Yarar MH; Ulu K; Coşkuner T; Yiğit RE; Baykal GÖ; Türkmen Ş; Çakan M; Demir F; Sözeri B
Clin Rheumatol; 2023 Jun; 42(6):1645-1653. PubMed ID: 36826737
[TBL] [Abstract][Full Text] [Related]
36. Ocular involvement in adult and paediatric patients with monogenic autoinflammatory diseases: a Spanish multicentre retrospective study.
Fonollosa A; Pelegrín L; García-Morillo S; Buján-Rivas S; Distefano L; Robles-Maruenda A; Fernández-Martín J; González-García A; Garcia-Aparicio Á; Ortego-Centeno N; Llorenç V; Sainz de la Maza M; Pinedo C; Sopeña B; Cocho L; Carreño E; Blanco R; Antón J; Pérez-Quintana M; Marques-Soares JR; Artaraz J; Ruiz-Arruza I; Soto-Peleteiro A; Gómez-Caverzaschi V; Araújo O; Espinosa G; Adan A; Fabiani C; Cantarini L; Hernández-Rodríguez J;
Clin Exp Rheumatol; 2023 Oct; 41(10):2105-2114. PubMed ID: 37812477
[TBL] [Abstract][Full Text] [Related]
37. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study.
Koné-Paut I; Lachmann HJ; Kuemmerle-Deschner JB; Hachulla E; Leslie KS; Mouy R; Ferreira A; Lheritier K; Patel N; Preiss R; Hawkins PN;
Arthritis Res Ther; 2011; 13(6):R202. PubMed ID: 22152723
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients.
Yokota S; Imagawa T; Nishikomori R; Takada H; Abrams K; Lheritier K; Heike T; Hara T
Clin Exp Rheumatol; 2017; 35 Suppl 108(6):19-26. PubMed ID: 27974104
[TBL] [Abstract][Full Text] [Related]
39. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.
Miyamoto T; Izawa K; Masui S; Yamazaki A; Yamasaki Y; Matsubayashi T; Shiraki M; Ohnishi H; Yasumura J; Kawabe T; Miyamae T; Matsubara T; Arakawa N; Ishige T; Takizawa T; Shimbo A; Shimizu M; Kimura N; Maeda Y; Maruyama Y; Shigemura T; Furuta J; Sato S; Tanaka H; Izumikawa M; Yamamura M; Hasegawa T; Kaneko H; Nakagishi Y; Nakano N; Iida Y; Nakamura T; Wakiguchi H; Hoshina T; Kawai T; Murakami K; Akizuki S; Morinobu A; Ohmura K; Eguchi K; Sonoda M; Ishimura M; Furuno K; Kashiwado M; Mori M; Kawahata K; Hayama K; Shimoyama K; Sasaki N; Ito T; Umebayashi H; Omori T; Nakamichi S; Dohmoto T; Hasegawa Y; Kawashima H; Watanabe S; Taguchi Y; Nakaseko H; Iwata N; Kohno H; Ando T; Ito Y; Kataoka Y; Saeki T; Kaneko U; Murase A; Hattori S; Nozawa T; Nishimura K; Nakano R; Watanabe M; Yashiro M; Nakamura T; Komai T; Kato K; Honda Y; Hiejima E; Yonezawa A; Bessho K; Okada S; Ohara O; Takita J; Yasumi T; Nishikomori R;
Arthritis Rheumatol; 2024 Jun; 76(6):949-962. PubMed ID: 38268504
[TBL] [Abstract][Full Text] [Related]
40. Interventions for reducing inflammation in familial Mediterranean fever.
Yin X; Tian F; Wu B; Xu T
Cochrane Database Syst Rev; 2022 Mar; 3(3):CD010893. PubMed ID: 35349164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
